Kentera (Oxybutynin)

Oxybutynin blocks muscarinic acetylcholine receptors in the detrusor muscle of the bladder. This antagonism reduces parasympathetic stimulation, leading to fewer involuntary contractions and a calmer bladder, which alleviates urgency, frequency, and incontinence.

The appropriate dose of Kentera is determined by the prescribing healthcare professional based on the patient’s condition, response, and tolerance. The prescriber will select the specific patch strength and application schedule that best fits the individual’s needs.

Safety data for oxybutynin in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Healthcare providers should weigh potential benefits against possible risks before prescribing it to pregnant or nursing women.

To order Kentera, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any required import documentation.

Kentera delivers oxybutynin via a transdermal patch, offering steady drug levels and potentially fewer gastrointestinal side effects compared with oral antimuscarinics. Other agents, such as solifenacin or tolterodine, are typically oral tablets and may have different efficacy or tolerability profiles depending on the patient.

Kentera should be stored at room temperature, preferably below 25 °C. Keep the patch in its original packaging, protect it from moisture, direct sunlight, and excessive heat to maintain its stability and effectiveness.

Kentera is a transdermal patch applied to clean, dry, intact skin on the upper torso or upper arm. The patch is worn for the prescribed duration, after which it is removed and disposed of according to local regulations. The skin site should be rotated with each new application.

Serious adverse reactions can include severe allergic responses such as anaphylaxis, urinary retention that may require catheterisation, cardiac arrhythmias like tachycardia, and hepatic dysfunction. Patients should seek immediate medical attention if they experience symptoms such as swelling, difficulty urinating, rapid heartbeat, or jaundice.

Kentera is contraindicated in patients with known hypersensitivity to oxybutynin or any patch components, those with narrow‑angle glaucoma, severe urinary retention, or uncontrolled cardiac arrhythmias. It should also be used with caution in individuals with significant hepatic or renal impairment.